» Articles » PMID: 34658162

Rational Design of a Modality-Specific Inhibitor of TRPM8 Channel Against Oxaliplatin-Induced Cold Allodynia

Overview
Journal Adv Sci (Weinh)
Date 2021 Oct 18
PMID 34658162
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Platinum-based compounds in chemotherapy such as oxaliplatin often induce peripheral neuropathy and neuropathic pain such as cold allodynia in patients. Transient Receptor Potential Melastatin 8 (TRPM8) ion channel is a nociceptor critically involved in such pathological processes. Direct blockade of TRPM8 exhibits significant analgesic effects but also incurs severe side effects such as hypothermia. To selectively target TRPM8 channels against cold allodynia, a cyclic peptide DeC-1.2 is de novo designed with the optimized hot-spot centric approach. DeC-1.2 modality specifically inhibited the ligand activation of TRPM8 but not the cold activation as measured in single-channel patch clamp recordings. It is further demonstrated that DeC-1.2 abolishes cold allodynia in oxaliplatin treated mice without altering body temperature, indicating DeC-1.2 has the potential for further development as a novel analgesic against oxaliplatin-induced neuropathic pain.

Citing Articles

TRPM channels in human cancers: regulatory mechanism and therapeutic prospects.

Liu Q, Hu M, Li S, Zhang X, Zhang R, Lyu H Biomark Res. 2024; 12(1):152.

PMID: 39633507 PMC: 11616203. DOI: 10.1186/s40364-024-00699-2.


β-Lactam TRPM8 Antagonists Derived from Phe-Phenylalaninol Conjugates: Structure-Activity Relationships and Antiallodynic Activity.

Martin-Escura C, Bonache M, Medina J, Medina-Peris A, De Andres-Lopez J, Gonzalez-Rodriguez S Int J Mol Sci. 2023; 24(19).

PMID: 37834342 PMC: 10573892. DOI: 10.3390/ijms241914894.


Camphor Attenuates Hyperalgesia in Neuropathic Pain Models in Mice.

Li Z, Gan Y, Kang T, Zhao Y, Huang T, Chen Y J Pain Res. 2023; 16:785-795.

PMID: 36925623 PMC: 10013580. DOI: 10.2147/JPR.S398607.


Simulation and Machine Learning Methods for Ion-Channel Structure Determination, Mechanistic Studies and Drug Design.

Zhu Z, Deng Z, Wang Q, Wang Y, Zhang D, Xu R Front Pharmacol. 2022; 13:939555.

PMID: 35837274 PMC: 9275593. DOI: 10.3389/fphar.2022.939555.


In Vitro and In Vivo Pharmacological Characterization of a Novel TRPM8 Inhibitor Chemotype Identified by Small-Scale Preclinical Screening.

Iraci N, Ostacolo C, Medina-Peris A, Ciaglia T, Novoselov A, Altieri A Int J Mol Sci. 2022; 23(4).

PMID: 35216186 PMC: 8877448. DOI: 10.3390/ijms23042070.


References
1.
Descoeur J, Pereira V, Pizzoccaro A, Francois A, Ling B, Maffre V . Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol Med. 2011; 3(5):266-78. PMC: 3377073. DOI: 10.1002/emmm.201100134. View

2.
Yang S, Yang F, Wei N, Hong J, Li B, Luo L . A pain-inducing centipede toxin targets the heat activation machinery of nociceptor TRPV1. Nat Commun. 2015; 6:8297. PMC: 4589873. DOI: 10.1038/ncomms9297. View

3.
Gao Y, Cao E, Julius D, Cheng Y . TRPV1 structures in nanodiscs reveal mechanisms of ligand and lipid action. Nature. 2016; 534(7607):347-51. PMC: 4911334. DOI: 10.1038/nature17964. View

4.
Vink S, Alewood P . Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain. Br J Pharmacol. 2012; 167(5):970-89. PMC: 3492980. DOI: 10.1111/j.1476-5381.2012.02082.x. View

5.
Perez de Vega M, Ferrer-Montiel A, Gonzalez-Muniz R . Recent progress in non-opioid analgesic peptides. Arch Biochem Biophys. 2018; 660:36-52. DOI: 10.1016/j.abb.2018.10.011. View